• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise...

cafead

Administrator
Staff member
  • cafead   Mar 24, 2023 at 10:22: AM
via The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.

article source